Skip to main content
ALLERGY THERAPEUTICS PLC logo

ALLERGY THERAPEUTICS PLC - Investor Relations & Filings

Listed IPO Oct 2004
Ticker · AGY ISIN · GB00B02LCQ05 LEI · 213800PQ7AHK7KGVOE23 IL Manufacturing
Open in API
Filings indexed 419 across all filing types
Latest filing 2026-06-30 Director's Dealing
Country GB United Kingdom
Listing IL AGY · 5 venues

Key figures FY2025

Period ended 2025-06-30 · GBP
Headline annual figures for ALLERGY THERAPEUTICS PLC, fiscal year 2025, reported in GBP, with the source filing for each figure.
Total Revenues GBP 55.04M per the Audit Report / Information filed 2025-12-11
Net Income GBP -40.13M per the Audit Report / Information filed 2025-12-11
Total Assets GBP 67.54M per the Audit Report / Information filed 2025-12-11
Total Equity GBP -28.19M per the Audit Report / Information filed 2025-12-11
Cash from Ops GBP -28.11M per the Audit Report / Information filed 2025-12-11

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About ALLERGY THERAPEUTICS PLC

https://allergytherapeutics.com/

Allergy Therapeutics PLC is an immunology company focused on the research, development, diagnosis, and treatment of allergic disorders. The company specializes in creating therapies for allergy treatment and prevention, with a key focus on developing aluminum-free immunotherapies and allergy vaccines. These treatments aim to address the underlying cause of the allergy rather than merely managing symptoms. Leveraging its specialist expertise in immunology, the company strives to develop effective and convenient solutions to improve the quality of life for individuals with allergies.

Recent filings

Filing Released Lang Actions
Vesting of Options under Long-Term Incentive Plan
Director's Dealing Classification · 100% confidence The document is an official notification regarding the vesting of share options under a Long-Term Incentive Plan (LTIP) for company directors (PDMRs). It includes the specific disclosure tables required by the UK Market Abuse Regulation for transactions by persons discharging managerial responsibilities. While it mentions remuneration, it is specifically a report of director dealings/transactions rather than a general remuneration policy report (DEF 14A). Therefore, it falls under the 'Director's Dealing' category.
2026-06-30 English
Long Term Incentive Awards
Director's Dealing Classification · 95% confidence The document is an official announcement regarding the grant of long-term incentive awards (LTIP) to the company's Chief Financial Officer. It includes a detailed table of the options granted, performance conditions, and a formal 'Notification and public disclosure of transactions by Director/persons discharging managerial responsibilities' (PDMR) section. While it involves remuneration, the primary nature of the filing is the disclosure of a director's share-based transaction/incentive award, which falls under the category of Director's Dealing (DIRS).
2026-06-15 English
Allergy Therapeutics to present at EAACI 2026
Regulatory Filings Classification · 95% confidence The document is a press release distributed via the RNS (Reach) service announcing that Allergy Therapeutics will be presenting research data and hosting a symposium at the EAACI Congress 2026. It provides summaries of clinical trial progress (PROTECT trial, G308 trial) but does not constitute a formal financial report, earnings release, or regulatory filing. It is a corporate announcement regarding scientific activities and conference participation, which falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2026-06-12 English
Interim Results for six months ended 31 Dec 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Results for the six months ended 31 December 2025' and contains comprehensive financial statements, including a consolidated income statement and statement of comprehensive income, along with detailed management commentary on financial and operational performance. It is not a mere announcement of a report, but the report itself, containing substantive financial data for a period shorter than a full fiscal year. H1 2026
2026-03-31 English
PDMR Dealings & Shareholding Update
Director's Dealing Classification · 100% confidence The document is an official notification regarding changes in shareholding structure and transactions by a Person Discharging Managerial Responsibilities (PDMR). It explicitly details share transfers and sales involving ZQ Capital and a director (Zheqing Shen), including a table formatted for 'Notification and public disclosure of transactions by Director/PDMR'. While it mentions shareholding updates, the primary regulatory purpose is the disclosure of director/PDMR dealings, which falls under the DIRS category.
2026-03-12 English
Positive Biomarker Results from PROTECT Trial
Regulatory Filings Classification · 95% confidence The document is an official announcement from Allergy Therapeutics PLC regarding positive biomarker results from a clinical trial (PROTECT Phase I/IIa). It is distributed via the Regulatory News Service (RNS) of the London Stock Exchange. While it discusses clinical trial results, it does not fit into specific financial reporting categories like 10-K or IR, nor is it a standalone audit report or management change. As it is a general regulatory announcement regarding company developments, it falls under the RNS category.
2026-03-04 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.